Г.Сарантуяа
Loading...
Товч нэр
Г.Сарантуяа
Бүтэн нэр
Гидаагаяа Сарантуяа
Латин нэр
Gidaagaya Sarantuya
Албан тушаал
Ахлах багш
ORCID
8 results
Now showing 1 - 8 of 8
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Quantitative Serum HBsAg and M2BPGi Levels in Patients with Chronic Hepatitis D(Mongolian National University of Medical Sciences, 2016-11-25); ; ; ;Uyanga BayarsaikhanSumiya DorjObjectives: Quantification of serum HBsAg has several clinical significances such as acting as a biomarker for the hepatitis D virus (HDV)-RNA level and necroinflammatory activity in HDV infection. The WFA+-M2BP is a new glyco-biomarker for liver fibrosis. The aim of this study was to compare the quantitative HBsAg and M2BPGi levels between groups of HBV infected patients with or without HDV infection. Methods: Totally, 112 consecutive HBsAg carriers with or without HDV infection (median age 36 vs 38) were enrolled in the study. Serum HBsAg and M2BPGi levels were measured using commercial tests. Results: Mean qHBsAg concentrations were 3.8 ±0.6 log IU/mL and 3.5 ±0.8 log IU/mL in the HDV positive and HDV negative HBsAg carriers, respectively (p = 0.02). Yet 45 patients out of 56 HDV positive patients have HBsAg level >2000 IU/mL whereas only 33 patients in the HBV mono infected group had concentrations this high. The mean M2BPGi was a 1.2 cut-off index (COI) in the HDV negative group vs. 2.1 COI in the HDV positive group (p<0.001). Conclusion: The qHBsAg level was higher in HDV positive patients compared with HDV negative subjects. But qHBsAg levels were higher in the HBeAg positive subjects despite the presence of HDV infection. The mean M2BPGi value in the HDV positive group was higher than in HDV negative subjects. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association Between IL-28B Polymorphism and Clinical Laboratory Features in Patients with Chronic Hepatitis D(Mongolian National University of Medical Sciences, 2017-11-25) ;Bayarsaikhan, Uyanga; ; Objectives: We aimed to determine an association between IL-28B rs12989760 single nucleotide polymorphism (SNP) and clinical laboratory parameters in patients with chronic hepatitis D. Methods: A total of 59 patients who were chronically infected with HDV were had their serum tested for the presence of qHBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc, anti-HCV, anti-HDV IgM, anti-HDV IgG, HDV RNA, HBV DNA and AFP. Liver function tests, coagulation tests and CBC were also performed. IL-28B polymorphism was performed using a TaqMan 5' allelic discrimination assay by real time PCR. Results: Of these 59 patients, 40 patients (67.8 %) carried the rs12979860CC homozygote genotype, 11 patients (18.6%) were rs12979860CC homozygote and 8 patients (13.6%) were rs12979860CT heterozygote. Alkaline phosphatase and direct bilirubin values were higher (p<0.05) and total protein levels were lower (p<0.05) in patients who were homozygotes for the T allele as opposed to the carriers of the C allele. AFP levels were significantly higher (p=0.02) in the rs12979860 TT genotype group. Liver enzymes including AST, ALT and GGT were significantly not higher in patients who carry C allele (p>.05). Conclusion: The most frequent genotype was IL-28B rs12979860CC among patients with chronic hepatitis D. The IL-28B rs12979860 polymorphism was associated with some abnormal liver function test parameters and AFP levels. Additional studies are necessary to understand the immune mechanisms of IL-28B polymorphism in HDV infection. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Measurement of Liver Fibrosis in Chronic Hepatitis D: Comparison of Invasive and Non-Invasive Methods(Mongolian National University of Medical Sciences, 2019-03-31); ;Dorj, Sumiya ;Jamsranjav, Selenge; Objectives: The aim of this study was to compare non-invasive methods in the detection of hepatic fibrosis in patients with chronic hepatitis delta. Methods: Twelve patients with chronic hepatitis delta who visited the Gastroenterology Department at the Intermed Hospital, were studied. Clinical and histological data were evaluated and serum indirect fibrosis markers including AST to ALT ratio, AST-to-Platelet Ratio, Fibrosis-4 index scores were calculated. Serum Mac-2 binding protein glycosylation isomer and liver stiffness measurements were performed in all participants. Results: Histological scoring showed that 16.7%, 41.7% and 41.7% of participants had F2, F3, and F4 stage of liver fibrosis, respectively. All participants were divided into groups; cirrhotic (F4) and non-cirrhotic (F0-F3). The median AST to ALT ratio in cirrhotic vs. noncirrhotic patients was 1.4 vs. 1.1 (p=.67), AST-to-Platelet ratios were 0.7 vs. 1.1 (p=.48), and Fibrosis-4 index scores were 1.8 vs. 1.6 (p=.82) in non-cirrhotic patients. Median Mac-2 binding protein glycosylation isomer levels in the cirrhotic group 1.3 cut-off index vs. 1.4 cut-off index in the non-cirrhotic group (p=.85). The median liver stiffness was 12.6 kPa in cirrhotic patients while 8.1 kPa in non-cirrhotic patients (p=.05). Conclusion: Non-invasive serum markers were less accurate in determining fibrosis in chronic hepatitis delta patients. Liver stiffness measurement was superior to the non-invasive serum markers. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Initial Trials With Susceptibility-Based and Empiric Anti-H. pylori Therapies in Mongolia(Frontiers Media SA, 2019); ; ; ; Background: Mongolia has a high prevalence of Helicobacter pylori infection and gastric cancer. We conducted a prospective, randomized, single-blind study to evaluate the efficacy of common regimens in Mongolia and to obtain specimens for susceptibility testing. Methods: Empiric treatments: 270 patients with confirmed H. pylori infection were randomized to receive 10 days clarithromycin-triple therapy (Clari-TT) (n = 90), modified bismuth quadruple therapy (M-BQT) (n = 90), or sequential therapy (ST) (n = 90). A second group of 46 patients received susceptibility-based Clari-TT. H. pylori was cultured from 131 patients and susceptibility testing was performed. H. pylori eradication was confirmed by stool antigen 4 weeks after the therapy. Results: Intention-to-treat (ITT) analysis cure rates were 71.1% (95% CI = 61.7-80.5%) for Clari-TT, 87.8% (95% CI = 81-94.6%) for M-BQT, 67.8% (95% CI = 58.1-77.5%) for ST vs. 89.1% (95% CI = 86-98.2%) for susceptibility-based Clari-TT. Per-protocol (PP) analysis results for these therapies were 72.7% (63.4-82%), 89.8% (83.5-96.1%), 68.5% (58.8-78.2%), and 97.6% (89.5-99.8%), respectively. Among 131 cultured H. pylori, resistance rates to amoxicillin, clarithromycin, and metronidazole were 8.4, 37.4, and 74%, respectively. Conclusion: In Mongolia, the prevalence of H. pylori resistance is high requiring bismuth quadruple therapy or susceptibility-based therapy to obtain acceptable cure rates.Scopus© Citations 12
